Human Trop-2 Monoclonal Antibody (N301Q)
Produktgrößen
1 mg
£268,00
YR0019-1MG
5 mg
£746,00
YR0019-5MG
20 mg
£1442,00
YR0019-20MG
Über dieses Produkt
- SKU:
- YR0019
- Zusätzliche Namen:
- EGP-1|EGP1|GA733-1|GA7331|GP50|M1S1|TACSTD2|TROP2
- Anwendung:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Klonalität:
- Monoclonal
- Weitere Details:
- Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2.Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Trop-2
- Isotyp:
- IgG1, kappa
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- ABclonal Technology
- Typ:
- Antibody: Biosimilar Antibody
- Datenblatt des Herstellers:YR0019